Predicting Antipsychotic Plasma Level Before Dosage Change: Population Pharmacokinetic Analysis

Predicting Antipsychotic Plasma Level Before Dosage Change: Population Pharmacokinetic Analysis - Predicting Antipsychotic Plasma Level

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002294

Enrollment

Registered

2009-08-20

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, schizophreniform disorder, delusional disorder, or psychotic disorder NOS (2) Having been treated with oral risperidone or olanzapine at a steady dose for at least 7 days (3) Antipsychotic dosage change is clinically indicated (4) Capable to provide informed consent

Exclusion criteria

Exclusion criteria: (1) Past history of vasovagal reflection associated with injection (2) History of treatment with long-acting risperidone within 3 months

Design outcomes

Primary

Measure	Time frame
An interclass correlation coefficient between predicted and observed plasma antipsychotic levels will be calculated.	—

Countries

Japan

Outcome results